Skip to main content
TipRanks
Go Ultimate75% OFF

Amarin (EH3) Q3 2026 Earnings Report

0 Followers

DE:EH3 Q3 2026 EPS Results

Actual EPS
EUR 0.00
Consensus EPS
-EUR 0.09
Beat/Miss
Beat by +EUR 0.09
One Year Ago EPS
-EUR 0.02

DE:EH3 Q3 2026 Revenue Results

Actual Revenue
EUR 35.34M
Expected Revenue
EUR 39.13M
Beat/Miss
Missed by -EUR 3.79M
YoY Revenue Growth
-19.91%

Earnings Announcement Details

Quarter
Q3 2026
Date
10/28/2026
Time
Before Open
Conference Call
Wednesday, October 28, 2026
DE:EH3 Upcoming Earnings

Amarin's next earnings date is estimated for March 3, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:EH3 Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Oct 28, 2026|% Change Since:-4.67%|
Earnings Call Sentiment|Positive

The call was predominantly positive, supported by the first profitable quarter in two years, four consecutive quarters of positive operating cash flow, a stronger debt-free balance sheet, lower expenses, improving supply economics, strong international in-market demand growth, maintained U.S. market leadership, and encouraging overall survival data from EMT2. These positives were tempered by lower total and U.S. revenue, continued U.S. pricing pressure, lower European product revenue, variability in partner ordering, uncertainty around 2027 exclusivity, and EMT2's failure to meet its primary progression-free survival endpoint.

Company Guidance

Management said its outlook for the full year remains positive, continued to expect positive operating cash flow for the full year, expected to maintain exclusivity with key payers through the end of 2026, and expected U.S. volumes to remain stable through year-end. It also expected U.S. pricing to remain relatively consistent through the end of this year, while stating it had not given guidance on 2027 and would anticipate continued pricing pressure into 2027. The company expects cost per unit to decline over time, with the benefit flowing through gradually, and said gross margin may vary from quarter to quarter based on sales mix and the timing and volume of partner shipments. Partners are preparing for launches in Singapore and South Korea in early 2027, while international product revenue is expected to contribute to increased partner supply purchases and related revenue over time, although purchases may not grow at the same rate as in-market demand in any given period.

  • First Profitable Quarter in Two YearsAmarin reported its first profitable quarter in two years, with third-quarter net income of $245,000, or less than $0.01 per share, compared with a net loss of $7.7 million, or $0.02 per share, in the third quarter of 2025.
  • Positive Operating Cash Flow and Stronger Balance SheetThird-quarter operating cash flow was positive at $9 million, while operating cash flow for the first nine months of 2026 totaled $22 million versus a $9 million cash outflow in the prior-year period. The company generated four consecutive quarters of positive operating cash flow, ended September with $324 million in cash and investments, up $21 million from year-end 2025, and remained debt-free.
  • Lower Operating Expense BaseTotal operating expense declined 44% year over year, driven largely by a 27% decline in SG&A and no restructuring expenses compared with $9.4 million in the prior-year quarter. Excluding restructuring costs, total operating expenses declined 22%, reflecting the lower go-forward cost structure established through the restructuring.
  • Improving Supply Economics and Gross MarginCost of goods sold declined to $23.4 million from $27.5 million in the prior-year period. Renegotiated supply contracts contributed to a sequential gross margin improvement, excluding write-offs, of approximately 2.3 percentage points despite continued U.S. pricing pressure.
  • Disciplined Inventory ManagementInventory declined 31% from Q4 2024, reflecting the company's stated focus on disciplined working capital management, aligning supply levels with demand and reducing capital tied up in the business.
  • Strong European In-Market Demand GrowthUnder the Recordati partnership, VAZKEPA in-market demand in Europe rose an estimated 68% in the third quarter of 2026 compared with the same period last year. Spain, the U.K., and Italy continued to produce strong results, and VAZKEPA was commercialized in 11 European countries as of September 30, with a private-pay launch in Poland in October.
  • Expanded European Commercial ReachRecordati holds rights to commercialize VAZKEPA across 59 countries and is pursuing reimbursement and market-entry activity beyond the markets where Amarin had previously commercialized the product. The company also stated that intellectual property protection extends through 2039.
  • Global Partner Demand GrowthAcross Amarin's global partner network, in-market demand for VASCEPA increased an estimated 55% in the third quarter year over year. Rest-of-World product revenue rose to $4.7 million from $3.6 million, while Rest-of-World in-market demand increased an estimated 46%.
  • Sustained International Demand GrowthInternational in-market demand increased an estimated 59% on a trailing 12-month basis compared with the preceding 12-month period, reflecting sustained growth beyond a single quarter.
  • Upcoming International LaunchesAmarin is supporting local partners in preparation for launches in Singapore and South Korea in early 2027, along with additional regulatory approvals and market launches across Southeast Asia.
  • Maintained U.S. IPE Market LeadershipAmarin maintained a 47% share of the U.S. IPE market while continuing to manage the business profitably. The company expects to maintain exclusivity with key payers through the end of 2026 and expects U.S. volumes to remain stable through year-end.
  • Licensing and Royalty Revenue GrowthThird-quarter licensing and royalty revenue increased to $2.7 million from $1.1 million in the third quarter of 2025.
  • Continued Scientific and Medical Affairs ActivityAmarin reported 28 publications, including abstracts, posters, and articles, year to date. Five investigator-led presentations at the European Society of Cardiology Congress provided additional analyses and mechanistic research related to icosapent ethyl, including treatment adherence, long-term outcomes, lipoprotein(a), coagulation biomarkers, and cardiovascular risk pathways.
  • Inclusion in European Cardiovascular and Kidney Disease GuidelinesThe European Society of Cardiology Congress featured the inclusion of icosapent ethyl in newly issued guidelines for managing cardiovascular disease and chronic kidney disease in collaboration with the European Renal Association.
  • EMT2 Overall Survival BenefitIn the investigator-initiated EMT2 phase III trial in 448 patients with colorectal cancer liver metastases, VASCEPA demonstrated a statistically significant 32% lower hazard of death on the key secondary endpoint of overall survival.
  • Potential Expansion of VASCEPA ResearchManagement stated that EMT2, together with mechanistic and investigator-initiated research, supports continued scientific investigation of highly purified EPA across broader biological effects and potential applications beyond cardiovascular care.
  • Positive Full-Year Outlook and Capital Allocation ReviewManagement said its full-year outlook remains positive and expects positive operating cash flow for the full year. The company is working with Barclays as exclusive financial advisor on shareholder-value efforts, with the discussions expected to inform the timing, scale, and prioritization of potential future capital deployment activities such as a share repurchase.

DE:EH3 Earnings History

DE:EH3 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 03, 20272026 (Q4)-0.08-0――
Oct 28, 20262026 (Q3)-0.090.00-0.02100.00% (+0.02)
Jul 29, 20262026 (Q2)-0.01-0.02-0.0333.33% (+0.01)
Apr 29, 20262026 (Q1)0.01-0.03-0.0425.00% (+0.01)
Feb 25, 20262025 (Q4)0.030.00-2.15100.00% (+2.15)
Oct 29, 20252025 (Q3)-0.38-0.02-1.0798.33% (+1.06)
Jul 30, 20252025 (Q2)-0.22-0.030―
May 07, 20252025 (Q1)-0.69-0.04-0.3690.00% (+0.32)
Mar 12, 20252024 (Q4)-0.95-2.15-0.18-1100.00% (-1.97)
Oct 30, 20242024 (Q3)-0.99-1.07-0.89-20.00% (-0.18)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed